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Objectives: To determine testosterone fractions in Japanese men and to compare these
values with those of Framingham Heart Study participants.
Methods: We enrolled 498 healthy Japanese men. Total testosterone was assayed by
liquid chromatography tandem mass spectrometry, sex hormone-binding globulin was
assayed by immunoassay and free testosterone was calculated by a laboratory at the Boston
Medical Center. Analog-based free testosterone and immunoassay-based total testosterone
were determined by immunoassay. We compared mass spectrometry assay-based total
testosterone and calculated free testosterone values in the Japanese participants with values
in the American Framingham Heart Study third generation cohort.
Results: The mean serum mass spectrometry assay-based total testosterone, sex
hormone-binding globulin, and calculated free testosterone values were 439.4 ± 167 ng/dL,
65.34 ± 30.61 nmol/L, and 58.75 ± 20.0 pg/mL, respectively. The correlation coefﬁcients with
age for mass spectrometry assay-based total testosterone, sex hormone-binding globulin,
and calculated free testosterone were 0.0010, 0.5041, and −0.496, respectively. There were
no age-related changes in mass spectrometry assay-based total testosterone values in
healthy men (P = 0.981), whereas sex hormone-binding globulin and calculated free testos-
terone levels showed similar age-related changes (P < 0.0001). Serum analog-based free
testosterone levels (8.24 ± 2.9 pg/mL) showed age-related changes (P < 0.0001) regardless
of immunoassay-based total testosterone levels (P = 0.828). Serum immunoassay-based
total testosterone values (486.1 ± 162.5 ng/dL) correlated with serum mass spectrometry
assay-based total testosterone values (r = 0.740, 95% conﬁdence interval 0.6965–0.7781,
P < 0.0001). Similarly, analog-based free testosterone and calculated free testosterone
values showed a highly signiﬁcant correlation (r = 0.706, 95% conﬁdence interval 0.6587–
0.7473, P < 0.0001). The analog-based free testosterone values were approximately 10% of
the calculated free testosterone values.
Conclusions: In contrast to the Framingham Heart Study cohort, total testosterone values
in Japanese men are not associated with advancing age; thus, they cannot be used to
diagnose late-onset hypogonadism in Japan. The analog-based free testosterone value can
be considered instead as a suitable biochemical determinant for diagnosing late-onset
hypogonadism syndrome.
Key words: aging, analog free testosterone, late-onset hypogonadism, sex hormone-
binding globulin, testosterone.
Introduction
LOH orTDS is a clinical and biochemical syndrome resulting from decreased serum testosterone
levels. LOH can negatively impact quality of life and adversely affect multiple organ systems.
Accordingly, serum testosterone measurement is the first step in diagnosing LOH and in assess-
ing androgen status.1,2
Measurement of TT is generally sufficient for diagnosing androgen excess or deficiency.
However, for suspected mild-to-moderate deficiency, measurement of FT is thought to be useful.
Currently, several testosterone fractions, includingTT, bioavailable testosterone, FT and cFT, can
be used to diagnose LOH. Most testosterone is bound to SHBG and to albumin, and, in general,
FT is thought to account for only 1–3% of the TT levels. Serum SHBG increases with age and
often affects the proportion of testosterone in each fraction.3
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Although isotope dilution equilibrium dialysis is recom-
mended for accurate FT measurement, this method is time-
consuming and is associated with technical difficulties. An
alternative is analog immunoassays, which are available for
detecting FT levels in clinical settings. However, analog
immunoassays have been widely criticized for their lack of
accuracy and for the variability of results with fluctuating
SHBG concentrations.4,5 These qualities suggest that the
immunoassays do not truly measure FT. A third alternative is to
calculate FT using equations based on the law of mass action.6–8
Many studies have evaluated age-related changes in serum
testosterone fractions in healthy men. However, just two major
studies have evaluated the testosterone levels in community-
dwelling men in Japan. Iwamoto et al.9 reported reference
values for serum iaTT and serum aFT, whereas Okamura et al.10
analyzed the serum levels of iaTT and cFT using RIA; iaTT in
community-dwelling men. Interestingly, neither study found
that serum TT declined with age in Japanese men, in contrast
with declines in FT with age.
However, other cross-sectional studies did show a decrease in
serum TT concentration with age.11,12 Longitudinal studies, the
Massachusetts Male Aging Study13 and the Baltimore Longitu-
dinal Aging Study14 all reported decreases in TT with increas-
ing age. Circulating testosterone in men is thought to decline
progressively by 0.4–2% per year from the third decade
onward.15 In addition, the ISA, ISSAM, EAU, EAA and ASA
recommend measuring serum TT to establish a diagnosis of
hypogonadism.
In contrast, the FHS is a long-term, ongoing cardiovascular
study of residents of the town of Framingham, Massachusetts,
USA. The study began in 1948 with 5209 adult participants
from Framingham, and is now on its third generation of par-
ticipants. The FHS participants, and their children and grand-
children, voluntarily consented to undergo a detailed medical
history, physical examination and medical tests every 2 years,
creating a wealth of data about physical and mental health,
especially about cardiovascular disease. Hormonal profile is
available for that study.
The present study used LC-MS/MS, immunoassay and cal-
culation to determine the testosterone fraction values in Japa-
nese men aged over 40 years. To investigate whether there are
ethnic differences in testosterone levels according to age, the




The present study was approved by the Ethics Committee of the
Kanazawa University Graduate School of Medical Science
(approval no. 40-H19). This cross-sectional study is part of the
project, “Clinical trial about the utility of the androgen replace-
ment therapy in late-onset hypogonadism syndrome” from
2007 to 2010. That study consisted of screening for healthy men
and a following intervention study of the candidates.
A total of 1682 participants were enrolled in the present
screening study and sera were obtained from all participants. Of
the 1682 participants, 498 were intentionally selected from
three areas, because enough of the sera in three groups could be
sent to the Hormone Assay Laboratory (Boston University
School of Medicine, Boston Medical Center, MA, USA) for
assay of hormonal parameters.
A total of 131, 92 and 275 participants, which were all
ethnically Japanese, were enrolled in Ishikawa (Kanazawa city),
Kanagawa (Kamakura city) and Tochigi (Nasushiobara city)
prefecture and the surrounding area, respectively.
A total of 131 participants were invited to participate in the
present study during their regular visits to a urologist and
general internist. The volunteers had no history of the presence
of any cancers and/or urinary retention as a result of benign
prostatic hyperplasia. Exclusion criteria included cirrhosis or
any other liver disease as well as serious psychiatric disorders,
use of mood stabilizers, psychotropic and anxiolytic agents, as
well as medications known to affect the endocrine system
and hypothyroidism. Blood samples were obtained between
08.00 hours and 10.00 hours.
Sera of 92 and 275 participants, who had a medical check-up
for a clinical survey of healthy men, were obtained. The blood
samples of these 367 participants were obtained at approxi-
mately 08.00 hours in the morning.
The present study was funded as part of the Longevity Sci-
ences study (grant no. H19-CHOJU-003, 1900000) by the Min-
istry of Health, Labor and Welfare, Japan.
TT, FT and SHBG measurements
Blood samples were immediately centrifuged at 4°C. The
serum was stored at −80°C until assays were carried out. Part of
each serum sample was sent to the Hormone Assay Laboratory
for TT, SHBG and cFT determinations in March 2012.
TT was assayed using the msTT. The functional limit of
detection, defined as the lowest concentration and detected with
less than 20% CV, was 2 ng/dL; no sample was outside the
linear range of 2–2000 ng/dL. Recovery was calculated by
adding known amounts of testosterone to charcoal-stripped
serum samples and analyzing the samples by LC-MS/MS. The
correlation between the amount added and the amount meas-
ured by LC-MS/MS was 0.998. The average recovery was
102 ± 3%. The cross-reactivity of DHEA, DHEAS, DHT,
androstenedione and estradiol in the testosterone assay was
negligible at 10-fold the circulating concentrations of these
hormones. The interassay coefficient of variation was 15.8% at
12.0 ng/dL, 10.6% at 23.5 ng/dL, 7.9% at 48.6 ng/dL, 7.7% at
241 ng/dL, 4.4% at 532 ng/dL and 3.3% at 1016 ng/dL.16 Ref-
erence ranges were not shown in the test report.
FT was calculated using a published law-of-mass-action
equation that utilizes an association constant estimated from a
systematic review of published binding studies and an iterative
numerical method.17 The intra- and interassay coefficients of
variation in the low, medium and high pools were 4.3% and
5.5%, 4.9% and 2.4%, and 8.1% and 2.5%, respectively. Ref-
erence ranges were not shown in the test report.
SHBG levels were measured using a two-site immuno-
fluorometric assay (DELFIA-Wallac, Turku, Finland).18,19 The
interassay CV were 8.3%, 7.9% and 10.9%, and the intra-assay
CV were 7.3%, 7.1%, and 8.7%, respectively, for the low,
medium and high pools. The analytical sensitivity of the assays
was 0.5 nmol/L. Reference ranges were shown as 12.9–
61.7 nmol/L in the test report.
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Comparison of TT and FT levels with the
levels in FHS participants
This current project is based on that longitudinal study. The
testosterone levels according to age were compared in Japanese
participants versus FHS participants; the FHS data is referred to
in Tables S1 and S2 in the literature for comparison.16 The
testosterone determinations were measured using the same
assay as in the current study.
Analog TT and FT measurements
Aliquots of each serum sample were sent to a laboratory (SRL,
Tokyo, Japan) for TT and aFT measurement. The iaTT was
measured with a commercial chemiluminescent immunoassay
(Architect Testosterone kit; Abbott Japan, Tokyo, Japan), and
aFT was measured using a kit from Diagnostic Products (Los
Angeles, CA, USA). The interassay CV were less than 15% for
both kits according to the manufacturer information.
Statistical analysis
Data were analyzed using GraphPad Prism version 5.04 for
Windows (GraphPad Software, San Diego, CA, USA; http://
www.graphpad.com). Parameter values are reported as means
and SD. Correlations between the immunoassay and mass spec-
troscopic values were determined using Pearson’s correlations.
Correlations of serum msTT and serum iaTT or serum aFT and
serum cFT were determined using Pearson’s simple and partial
correlation coefficients. Differences were considered statisti-
cally significant at P < 0.05.
Results
Participants
Initially, 498 men were enrolled in the study. The mean partici-
pant age was 60.5 ± 12.9 years (median 60 years, range
40–90 years). The distribution of participants by age is shown
in Figure 1. Of the 498 participants, the iaTT of 20 could not be
assayed, as the sample volumes were insufficient. The mean age
of the cohort after exclusion of these 20 participants (n = 478)
was 60.6 ± 13.0 years (median 59 years, range 40–90 years).
Testosterone and SHBG according to age
The mean serum msTT value was 439.4 ± 167 ng/dL (range
139.4–1378 ng/dL, n = 498), and the median value was
420 ng/dL (Fig. 2a). The mean serum SHBG value was 65.34 ±
30.61 nmol/L (range 10.70–233.8 nmol/L, n = 498), and the
median value was 59.55 nmol/L (Fig. 2b). The mean cFT value
was 58.75 ± 20.0 pg/mL (range 16.0–150.8 pg/mL, n = 498),
and the median value was 56.90 pg/mL (Fig. 2c). These three
determinations were carried out by the HormoneAssay Labora-
tory at Boston University.
Serum msTT levels showed no significant decrease with
increasing age in healthy men (P = 0.981). The correlation
coefficient with age for serum msTT level was 0.0010 (95% CI
−0.08684–0.08894). In contrast, the correlation coefficients
with age for serum SHBG and cFT levels were 0.5041 (95% CI
0.4355–0.5668) and −0.496 (95% CI −0.5619 to −0.4295),
respectively. These correlations were significantly different for
age (P < 0.0001). Even though the serum msTT level showed
no age-related changes, serum SHBG and serum cFT levels
showed very similar age-related changes.
Comparison of serum msTT and serum cFT
between the FHS and in the present study
according to age
Figure 3 shows the relationships of serum msTT and cFT
values in the FHS cohort and in the present cohort according to
participant age with age stratified by decade. Even though the
mean serum msTT did not decline with age in the current
cohort, TT was associated inversely with age in the FHS broad
sample.16 The mean serum msTT value in the current samples
was approximately 70–80% lower than the mean value in the
FHS cohort (Fig. 3a). Furthermore, the cFT values decreased
with age in both groups. The mean cFT value in the current
cohort was approximately 60–70% lower than in the FHS broad
sample (Fig. 3b).
Comparison of serum iaTT and serum aFT
according to age
The mean serum iaTT value was 486.1 ± 162.5 ng/dL (range
135.0–1100 ng/dL, n = 478), and the median value was
472.0 ng/dL (Fig. 2d). The mean serum aFT value was
8.25 ± 2.9 pg/mL (range 21.5–1.90 pg/mL, n = 498), and the
median value was 8.1 pg/mL (Fig. 2e). Serum iaTT levels
showed no significant decrease with increasing age in healthy
men (P = 0.828). The correlation coefficient with age for the
serum iaTT level was 0.0102 (95% CI −0.0796–0.0998). In
contrast, the correlation coefficient with age for serum aFT
levels was −0.458 (95% CI −0.525 to −0.3861). The correlation
was significantly different in age (P < 0.0001). The serum iaTT
level showed no age-related change, whereas the serum aFT
levels in both cohorts showed very similar age-related changes.
Correlation analysis of serum msTT and
serum iaTT
Serum iaTT measurements were moderately correlated with the
corresponding measurements of serum msTT (Pearson’s
r = 0.740, 95% CI 0.6965–0.7781, P < 0.0001, n = 478). The















Fig. 1 Distribution of participants according to age by decade.
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analog and LC-MS/MS measurements; the serum iaTT
values were higher than the serum msTT values, as many
samples were over the unity line. The mean serum msTT
value (439.4 ± 166.7 ng/dL) was approximately 90% lower
than that of serum iaTT (486.1 ± 162.5 ng/dL), and this
difference was significant (P < 0.0001; Table 1). Thus,
LC-MS/MS results in significantly lower serum testosterone
values than those determined by immunoassay; this could be as


























































































Fig. 2 Scatter blots showing the results of (a)
msTT, (b) SHBG, (c) cFT, (d) iaTT (e) and aFT accord-

































Fig. 3 Comparison of the FHS cohort and the
present study cohort using (a) serum msTT and (b)
cFT according to participant age. The ﬁlled circles in
red and squares in green represent FHS and current
participants, respectively. Vertical lines indicate the
































Fig. 4 Correlation analysis. (a) Serum TT deter-
mined using iaTT and msTT and (b) aFT and cFT. In
each panel, the solid line indicates the regression
relationship and the dashed line represents a slope
of unity. The ratio of Y to X is (a) 1.0 and (b) 0.1,
respectively.
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Correlation analysis between serum aFT and
serum cFT
Serum aFT values were moderately correlated with cFT values
(Pearson’s r = 0.706, 95% CI 0.6587–0.7473, P < 0.0001,
n = 498).When using aFT values versus cFT values, it is impor-
tant to note the strong and highly significant correlation of these
two assays. As reported previously, the aFT values are lower
than the cFT values.22 In the present study, the regression equa-
tion was Y = 0.1017X + 2.270. The values for aFT were also
lower by approximately 10% than the cFT values (Fig. 4b). As
shown in Figure 4b, the slope of regression shifted upwards.
Discussion
LOH, also referred to as age-associated TDS, has specific clini-
cal and biochemical features. Accurate testosterone level deter-
mination is essential for the diagnosis of LOH. Bhasin et al.
determined the reference limits for TT and FT concentrations in
a community-based sample of healthy men who were aged
19–40 years using data from the FHS third generation
cohort.
The FT level was calculated. Values below the 2.5th percen-
tile of the reference sample (n = 456) were considered low
testosterone values. The 2.5th percentile values were
348.3 ng/dL for TT and 70.0 pg/mL for FT. They showed that
values below the proposed lower reference limits were associ-
ated with increased risks for conditions that were previously
associated with androgen deficiency in one or more cohorts.18,23
One large study carried out in 1143 community-dwelling
Japanese men aged 20–77 years generated reference testoster-
one ranges. Specifically, Iwamoto et al. determined serum iaTT
and serum aFT levels using RIA (iaTT).9 In a second study,
Okamura et al. analyzed the levels of serum TT and cFT in
1120 community-dwelling Japanese men aged 40–79 years
using RIA (iaTT); however, they could not use the term “ref-
erence ranges” in their study, because they did not follow the
formal procedures to determine reference ranges as proposed
by the National Committee for Clinical Laboratory Standards.
Nevertheless, their serum samples were from community-
dwelling men and the determined values were used to evaluate
LOH.
Table 1 shows the serum iaTT values in the three studies
carried out in Japan. The serum iaTT values did not decrease
with age in any of these studies. The mean serum iaTT values
according to age by decade in Iwamoto’s study were lower than
those in the Okamura et al. study and in the current study, even
though the same assay was used.
Although different commercially available assay kits might
give different testosterone values, it appears that themean serum
iaTT value (4.37 ng/mL) is relatively lower in Iwamoto’s study,
which determined testosterone levels in healthy community-
dwelling men. The serum iaTT values in the Iwamoto study and
the current study were (mean [+2SD to −2SD]) 4.32 ng/mL
(7.5–2.01 ng/mL) and (mean ± SD) 486.1 ± 162.5 ng/dL
(4.86 ± 1.63 ng/mL), respectively. As the mean value as deter-
mined in the Iwamoto study was relatively low, it is likely to
produce bias inclusion of men aged in their 20s and 30s. In fact,
we did not measure the values in men aged in their 20s and 30s,
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In the current study, the serum iaTT values were higher than
the serum msTT values in men aged 40–80 years or older.
Figure 3a shows the serum msTT in the FHS and current
cohorts according to age by decade. The serum msTT value in
the current sample was approximately 70–80% lower than that
of the FHS broad sample. The distribution of TT levels by
decades of age was 10–20% higher in the FHS than in the other
two cohorts (the MrOS and the EMAS cohorts).16 A study of an
age-stratified, random sample of Rochester (MN, USA) men
aged 22–93 years included 325 men, with approximately 50
men per decade. The means serum msTT and iaTT values were
467.8 ± 173.4 ng/dL and 492.9 ± 196.2 ng/dL.24 The TT values
in the current cohort is nearly the same as these in three cohorts.
Therefore, it appears likely that the values of msTT in the FHS
samples were actually higher contrary to expectations.
There is considerable controversy regarding the best method
for measuring FT. Although equilibrium dialysis is widely
accepted as the ‘gold standard’ for measuring FT,25 it is consid-
ered laborious, slow and costly.26 There are few laboratories that
assay FT using the equilibrium dialysis method in Japan. To
evaluate FT, the Iwamoto study used an analog FT assay, the
Okamura study utilized the equilibrium-binding theory using
TT, SHBG and albumin values,6 and the current study utilized
the law-of-mass-action equation as described in the Materials
and Methods.17
Table 2 shows the FT values determined in the three studies
carried out in Japan. All three studies found that serum aFT and
cFT levels decreased with age (Fig. 2c). The mean serum aFT
values according to age by decade in the current cohort were
lower than those in the Iwamoto study; both studies used the
same detection kit. The mean cFT values according to age by
decade in the current cohort were also lower than those in the
Iwamoto study, and the mean aFT values according to age by
decade in the current cohort were lower than those in the
Okamura study. Figure 3b shows that the cFT values in the
current cohort were approximately 70–80% lower than in
the FHSbroad sample.The FTvalues according to age by decade
were 10–20% higher in the FHS cohort than in the other two
cohorts (i.e. the MrOS and the EMAS cohorts).16 Therefore, it is
likely that the cFT values in the FHS cohort were higher.
There is general agreement that approximately 44% of the
circulating testosterone is strongly bound to SHBG, 54% is
loosely bound to albumin and 2% is present as free
hormone.2,27,28 The mean values of serum SHBG according to
age by decade in the current study were very high compared
with those determined in participants in a cross-sectional study
of 400 independently-living European and American men aged
between 40 and 80 years.29
The mean SHBG values by decade of age were 34.7 nmol/L
for men aged in their 40s, 38.0 nmol/L for men aged in their
50s, 43.6 nmol/L for men aged in their 60s and 46.1 nmol/L for
men aged in their 70s. The participants of the Rochester study
had a median serum SHBG value of 33.3 nmol/L (quartiles:
24.9–48.3 nmol/L).24 The mean SHBG values by decade were
approximately twice those of the current sample compared with
values reported in the literature (Table 2).
Biological factors, such as interindividual variability or
ethnic factors, could account for this variation. It is unclear why
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GH and IGF-I levels might contribute to the increase.30
However, SHBG measurements were strikingly different in dif-
ferent studies, so differences might be due in part to inaccurate
measurements.
In conclusion, the present large cross-sectional study showed
that the TT level did not decrease with age in this Japanese
cohort, in contrast to findings in the FHS cohort. Thus, the TT
level cannot be used to diagnose LOH in Japan, even though it
is recommended for use in European and American popula-
tions. However, the aFT can be used as a convenient biochemi-
cal determinant for diagnosing LOH syndrome in Japanese
men. Future studies should consider that these determinants
and SHBG might impact the associations between circulating
testosterone fractions and associated clinical conditions.
Furthermore, these determinants could be used to define target
populations for male hormone replacement therapy.
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